



ICICI Prudential Life Insurance

Estimate change TP change Rating change

Motilal Oswal values your support in the Asiamoney Brokers Poll 2020 for India Research, Sales and Trading team. We request your ballot.



Bloomberg	IPRU IN
Equity Shares (m)	1,435
M.Cap.(INRb)/(USDb)	636.5 / 8.4
52-Week Range (INR)	538 / 222
1, 6, 12 Rel. Per (%)	4/-1/18
12M Avg Val (INR M)	1301

Financials & Valuations (INR b)

Y/E MARCH	FY20	FY21E I	FY22E
Net Premiums	329	338	355
Surplus / Deficit	21.9	12.9	14.6
Sh. holder's PAT	10.7	11.5	12.4
NBP growth unwtd (%)	20.5	5.0	10.0
APE growth - (%)	-2.9	-8.1	18.2
Tot. Premium gr. (%)	8.0	2.5	5.0
VNB margin (%)	21.7	23.8	24.6
RoE (%)	15.0	15.1	14.7
RoEV (%)	6.5	14.5	14.6
Total AUMs (INRt)	1.5	1.7	1.8
VNB (INRb)	16.0	15.5	19.0
EV per share	160	184	210
Valuations			
P/EV (x)	2.8	2.4	2.1
P/EPS (x)	59.5	55.3	51.3

Shareholding pattern (%)

As On	Jun-20	Mar-20	Jun-19			
Promoter	73.5	75.0	75.0			
DII	5.2	5.5	6.3			
FII	15.1	13.3	11.5			
Others	6.2	6.1	7.2			
FII Includes depository receipts						

CMP: INR443 TP: INR510 (+15%) Buy ULIPs weigh down premium growth; Outlook modest Rising mix of Protection business drives further margin improvement

- IPRU Life's (IPRU) business trends were weak due to the COVID-19 led lockdown and subdued buyer sentiment toward capital market linked insurance and investment products. APE growth declined 44% YoY led by 66% YoY drop in ULIPs while other segments maintained steady trends. Persistency declined further with 13th/25th month persistency dropping 140bp/170bp QoQ. However, it is recovering and is above the assumptions incorporated in EV calculations.
- 1QFY21 VNB declined 35% YoY; however, management has reiterated its intention to double FY19 VNB guidance over the next 3-4 years. VNB margins improved to 24.4%, led by sharp increase in Protection mix of 26% (v/s 15% in FY20).
- We expect continued buoyancy in the Protection business along with gradual recovery in ULIPs to drive business /VNB growth over the near term while persistency should move in a narrow range. Maintain Buy with revised PT of INR510.

VNB margins expand led by protection business; Cost ratios improve

- 1QFY21 PAT was flat YoY at INR2.9b, supported by strong opex control even as business growth was weak. Gross premium income decline ~9% YoY, led by 51% YoY decline in first-year premium while single premium declined 4% YoY.
- Renewal premium grew a modest 2.4% YoY as persistency declined slightly. 13th/25th month persistency dropped by 140bp/170bp QoQ; however, it is recovering and is above the assumptions incorporated in the EV calculations.
- In 1QFY21, total APE declined ~44% YoY led by ULIPs, which plunged 66% YoY. Protection APE growth stood flat; however, its share in overall business mix improved to 26% (15.1% in FY20). Share of ULIPs declined to 44% (~65% in FY20 v/s ~80% in FY19).
- VNB margins improved to 24.4% (21.7% in FY20) due to higher mix of Protection business; however, sharp decline in business volumes resulted in 35% YoY decline in VNB to INR2.0b.
- Total operating expenses (incl. commissions) declined 23% YoY, and thus, cost to total weighted received premium declined to 14.8% (15.9% in FY20 and 17.0% in 1QFY20).

Highlights from management commentary

- IPRULIFE has launched a new Protection product in Jul'20 and expects margins to improve further as the new product pricing is 10-25% higher v/s the old policy. Overall, increase in pricing should neutralize the impact of re-insurance hike.
- Entered into partnership with IDFC First Bank to sell life insurance policies.

Research Analyst: Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com); +91 22 6129 1542 | Himanshu Taluja (Himanshu.Taluja@motilaloswal.com)

Alpesh Mehta (Alpesh.Mehta@MotilalOswal.com); Yash Agarwal (Yash.Agarwal@motilaloswal.com)

2

Valuation and view

Protection/annuity segments are likely to see healthy growth and should help drive steady margins (24.6% by FY22E). ULIP business growth should remain sluggish in the near term given weak buyer sentiment toward capital market linked insurance and investment products. The continued buoyancy in the Protection business along with gradual recovery in ULIPs should drive business /VNB growth in the near term, even as persistency moves in a narrow range. We remain watchful of surrenders in the ULIP business given the sharp revival in the equity markets. We estimate IPRU Life to deliver CAGR of ~13% in VNB over FY19-22E, largely led by continued expansion in VNB margin while operating RoEV should sustain at ~15%. Maintain Buy with a revised target price of INR510 (2.4x FY22E EV).

Quarterly performance												(INRm)
Policy holder's A/c		F	Y20			FY	'21 E		FY20	FY21E	1Q	A v/s E
(INR m)	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE	F120	FIZIE	FY21E	A V/S E
Net premium income	62,081	80,647	81,310	104,751	55,511	74,425	87,957	120,403	328,790	338,296	50,744	9%
Growth (%)	14.2%	6.1%	8.7%	4.2%	-10.6%	-7.7%	8.2%	14.9%	7.5%	2.9%	-18.3%	
Commission paid	2,648	3,945	4,277	4,433	2,067	4,311	5,095	8,122	15,860	19,595	2,939	-30%
Operating expense	6,458	7,542	7,662	7,365	4,939	7,094	8,384	11,828	28,469	32,244	4,837	2%
Surplus/(Deficit)	4,221	4,768	3,870	9,011	6,311	2,828	3,342	372	21,870	12,854	1,978	219%
Shareholder A/c												
Total income	5,122	6,015	5,482	9,868	7,737	4,034	4,736	1,033	26,487	17,541	3,420	126%
PBT	2,870	3,063	3,038	1,717	3,112	2,740	3,216	2,558	10,687	11,912	2,294	36%
PAT	2,849	3,019	3,025	1,795	2,876	2,644	3,104	2,586	10,687	11,495	2,214	30%
Growth (%)	1.2%	0.3%	1.9%	-31.3%	0.9%	-12.4%	2.6%	44.1%	-6.3%	7.6%	0	
Key metrics												
VNB (INRb)	3.1	4.0	4.3	4.7	2.0	3.2	3.9	6.3	16.0	15.5	2	
AUM (INRb)	1,640	1,655	1,720	1,530	1,700	1,570	1,611	1,665	1,530	1,665	1,548	
EV (INRb)	NA	227	NA	230	0	240	250	263	230	263	234	
VNB Margins (%)	21.0	21.0	21.0	21.7	24.4	22.6	22.7	23.5	21.7	23.8	22	
Solvency ratio (%)	217	211	207	194	190	185	180	189	194	189	190	

E:MOFSL Estimates

21 July 2020

 $Motilal\ Oswal$

Quarterly snapshot

Policyholder A/c	FY19			FY20				FY21	Chang	e (bp)	
(INR b)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	YoY	QoQ
Net premium income	54.4	76.0	74.8	100.6	62.1	80.6	81.3	104.8	55.5	-11	-47
First year premium	12.6	18.4	16.4	22.4	12.7	17.2	18.7	16.5	6.3	-51	-62
Renewal premium	37.5	51.0	50.1	67.1	40.4	52.4	52.3	64.4	41.4	2	-36
Single premium	5.1	7.4	9.2	12.2	10.2	12.3	11.6	25.7	9.8	-4	-62
Investment income	23.2	12.3	10.5	56.2	19.9	-1.3	45.6	-189.4	130.7	556	-169
Total income	78.7	88.3	86.5	160.5	84.3	82.1	129.5	-76.5	190.6	126	-349
Commission paid	2.8	4.0	3.7	5.1	2.6	3.9	4.3	4.4	2.1	-22	-53
Operating expenses	6.0	6.6	5.8	7.7	6.5	7.5	7.7	7.4	4.9	-24	-33
Total commission & opex	8.7	10.5	9.5	12.8	9.1	11.5	11.9	11.8	7.0	-23	-41
Benefits paid	29.4	35.0	33.2	44.9	36.4	41.4	53.9	62.0	26.0	-29	-58
Provisions	1.5	1.6	1.6	1.7	1.9	2.6	1.7	2.4	1.6	-16	-33
Total expenses	75.4	86.0	82.9	156.2	79.8	77.1	125.4	-86.1	184.0	131	-314
PBT	3.3	2.3	3.5	4.3	4.5	5.0	4.1	9.6	6.5	45	-32
Tax	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.6	0.2	-22	-60
Surplus/(Deficit)	3.0	2.0	3.3	4.1	4.2	4.8	3.9	9.0	6.3	50	-30
Shareholder A/c											
Trf from policyholder a/c	2.5	1.5	2.7	4.2	3.7	4.0	3.6	8.6	6.5	75	-25
Investment Income	1.4	1.4	1.4	2.2	1.4	2.0	1.9	1.3	1.3	-11	1
Total income	3.9	2.9	4.0	6.5	5.1	6.0	5.5	9.9	7.7	51	-22
PBT	2.8	3.0	3.0	2.8	2.9	3.1	3.0	1.7	3.1	8	81
Tax	0.0	0.0	0.0	0.2	0.0	0.0	0.0	-0.1	0.2	1,051	-401
PAT	2.8	3.0	3.0	2.6	2.8	3.0	3.0	1.8	2.9	1	60
APE data										Chang	e (bp)
Savings APE	12.8	18.3	17.7	22.0	12.6	16.2	17.7	16.2	6.1	-51	-62
ULIP	11.1	16.6	15.5	18.9	10.5	12.8	13.8	10.7	3.6	-66	-66
Participating	1.4	1.4	1.7	2.3	1.4	2.2	2.5	2.5	0.0	-100	-100
Other Savings	0.3	0.3	0.5	0.8	0.7	1.2	1.4	3.0	2.5	268	-18
- Non-Participating	0.1	0.1	0.2	0.3	0.2	0.3	0.2	3.1	2.0	905	-36
- Group	0.2	0.2	0.3	0.5	0.5	0.9	1.2	-0.1	0.5	2	-590
Protection	1.1	1.5	2.0	2.6	2.1	2.8	2.7	3.5	2.1	0	-39
Total APE	14.0	19.8	19.6	24.6	14.7	19.0	20.4	19.7	8.2	-44	-58

Ö	uarterl	v sna	nshot	contd.
ч	uaiteii	y Jiia	pariot	conta.

Ratios (%)		FY	19			FY	'20		FY21	Chang	e (bp)
Ratios (%)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	YoY	QoQ
APE (% of total)											
Savings APE (%)	91.8	92.3	90.1	89.4	85.4	85.1	86.9	82.2	74.0	-1,138	-817
ULIP	79.8	83.8	78.9	76.7	71.2	67.2	67.8	54.1	43.6	-2,754	-1,048
Participating	9.7	6.8	8.8	9.3	9.7	11.5	12.3	12.7	0.0	-966	-1,266
Other Savings	2.3	1.7	2.4	3.3	4.6	6.4	6.8	15.4	30.4	2,575	1,498
Protection	8.2	7.7	9.9	10.6	14.6	14.9	13.1	17.8	26.0	1,144	817
Distribution mix (%)											
Banca	55.6	56.7	57.0	54.3	52.4	53.2	53.6	44.3	39.6	-1,285	-476
Agency	21.8	22.3	20.5	22.0	21.2	19.8	21.9	21.7	24.6	347	295
Direct	11.7	11.9	11.2	12.8	12.8	13.0	11.7	13.0	12.3	-54	-76
Corporate Agents	6.5	5.1	5.6	6.4	6.8	7.3	7.2	8.2	8.6	181	46
Group	4.4	4.1	5.7	4.5	6.8	6.7	5.6	12.8	14.9	812	211
Key Ratios (%)											
Operating ratios											
Commission (unwtd)	5.5	5.6	5.5	5.8	5.1	5.3	5.5	5.7	4.2	-90	-150
Opex (unwtd)	12.0	10.5	9.9	9.3	11.9	11.3	11.1	10.3	10.5	-140	20
Total Cost (unwtd)	17.5	16.1	15.4	15.0	17.0	16.6	16.6	15.9	14.8	-220	-110
Solvency Ratio	234.6	234.3	224.3	214.9	216.7	210.6	207.2	194.1	205.1	-1,160	1,100
VNB margins	17.5	17.5	17.0	17.0	21.0	21.0	21.0	21.7	24.4	340	270
Persistency ratios											
13th Month	85.8	85.2	84.1	84.6	84.4	83.6	83.1	83.2	81.8	-260	-140
25th Month	77.8	77.8	76.7	75.6	75.7	75.0	74.4	75.1	73.4	-230	-170
37th Month	68.2	68.3	68.7	69.3	69.8	69.1	68.3	66.7	65.4	-440	-130
49th Month	63.7	63.7	63.2	63.8	64.2	63.7	64.3	64.6	63.9	-30	-70
61st Month	54.0	54.8	55.6	56.8	57.3	57.2	56.3	56.0	56.8	-50	80
Key Metrics (INRb)											
VNB	2.4	3.5	3.2	4.2	3.1	4.0	4.3	4.7	2.0	-35	-57
AUM	1427	1461	1500	1604	1640	1655	1720	1530	1700	4	11

Note: (a) Persistency ratios are excluding single premium, (b) All ratios are on cumulative basis for 1H, 9M and 12M



Highlights from management commentary

Operating metrics

- IPRULIFE witnessed some deferral in renewal premium due to grace period offered to customers, which led to slight drop in persistency. However, the company expects persistency trends to revert to normalcy in the coming quarters.
- The increase in VNB margins is primarily on account of increase in the Protection mix in the total APE. However, VNB margins in the Protection segment have contracted as entire re-insurance hike has not been passed. Nevertheless, it has launched new product Jul'20 onwards, which has relative higher pricing and will neutralize the impact of re-insurance hike and further support VNB margins.
- Levers for cost reduction to lower rental cost and manage discretionary expenses, etc.
- It continues to reiterate its guidance of doubling VNB over 3-4 years.

Business mix

- IPRULIFE is witnessing better trends in the Non-Linked Savings business (14% YoY) while it is continuing to witness pressure in the Linked business (declined 66% YoY).
- Further, it is witnessing strong traction in the Protection/Annuity segment, which will remain a key focus in the near term. The share of Protection in total APE improved to 26% during 1QFY21

21 July 2020


- In terms of individual sum assured, IPRULIFE's performance remains better compared to peers.
- On the other hand, persistency in the ULIP segment has dropped while it has improved in the Protection segment.
- IPRULIFE has launched a new term plan from Jul'20, and thus, expects margins to improve further. The new product prices are 10-25% higher v/s old premiums. Overall, increase in pricing is to neutralize impact of the re-insurance hike
- The percentage of risk retained in the Protection business is 50% and the rest is passed to the re-insurer.
- Only received 69 claims so far due to COVID-19.
- Some sectors have seen increased risk due to the COVID-19 pandemic. However, it has only 0.9% of fixed income exposure below AA rated.
- Non-par guaranteed return book is very minimal i.e. 0.4% of liabilities, and thus, has minimum ALM mismatch.
- Credit life business was affected significantly during the quarter. It is ~70% lower due to pre-COVID trends.
- Protection and non-linked business contributes 74% of total VNB.

Others

Entered into partnership with IDFC First Bank to sell Life Insurance policies.


Key Exhibits

Exhibit 1: Protection mix improves to ~26% of total APE v/s ~15% in 1QFY20




Source: MOFSL, Company

Exhibit 2: Margins expanded 340bp YoY to 24.4% on back of improved Protection mix (~26%% v/s ~15% in 1QFY20)




Source: MOFSL, Company

Exhibit 3: Total expense ratio stood at 14.8% (-220bp YoY)



Source: MOFSL, Company

Exhibit 4: Staff cost declined 18% YoY



Source: MOFSL, Company


Valuation view

- We believe the Indian life insurance sector is in a sweet spot, where strong structural potential is now overlapping with rising share of financial savings and higher disposable income. We, thus, expect Indian insurers to trade at a premium to global insurers.
- Private sector life insurance companies have 44% market share in total new business APE, and IPRU is amongst the leading players to reflect market share gains across segments
- Protection and Annuity are likely to do well as they are relatively simpler products and easy to transact through the Digital channel. Thus, we expect the share of Protection/Non-PAR to increase, driving further margin expansion. Overall, we expect VNB margins to improve to ~25% by FY22E.
- Buy with target price of INR510: Protection/Annuity segments are likely to see healthy growth and should help drive steady margins (24.6% by FY22E). ULIP business growth is likely to remain sluggish in the near term given weak buyer sentiment toward capital market linked insurance and investment products. The continued buoyancy in Protection business along with gradual recovery in ULIPs should drive business/VNB growth over the near term while persistency continues to move in a narrow range. We remain watchful of surrenders in ULIP business given the sharp revival in equity markets. We estimate IPRU Life to deliver CAGR of ~13% in VNB over FY19-22E, largely led by continued expansion in VNB margin while operating RoEV should sustain at ~15%. Maintain Buy with a revised target price of INR510 (2.4x FY22E EV).

MOTILAL OSWAL ICICI Prudential Life Insurance


Story in Charts

Exhibit 5: First year premium declined 51% YoY




Source: MOFSL, Company

Exhibit 6: Share of single premium declined to 18%




Source: MOFSL, Company

Exhibit 7: Share of bank partners declining




Source: MOFSL, Company

Exhibit 8: Share of ULIP in total APE declined to 44%




Source: MOFSL, Company

Exhibit 9: 13th/25th month persistency declined



Source: MOFSL, Company

Exhibit 10: Solvency ratio stood at 205%, above the regulatory requirement of 150%



Source: MOFSL, Company

MOTILAL OSWAL ICICI Prudential Life Insurance

Financials and Valuations

- 1 : 1 : (0.01)	5)/4 5	51/40	=\(\frac{1}{2}\)	EVO	EV045	EVOOF
Technical account (INR b)	FY17	FY18	FY19	FY20	FY21E	FY22E
Gross Premiums	223.5	270.7	309.3	334.3	342.5	359.7
Reinsurance Ceded	(2.0)	(2.6)	(3.5)	(5.5)	(4.2)	(4.5)
Net Premiums	221.6	268.1	305.8	328.8	338.3	355.2
Income from Investments	149.8	112.6	102.1	(125.2)	92.0	126.9
Total income (A)	371.9	382.2	414.0	219.4	442.7	496.3
Commission	7.6	14.0	15.5	15.9	19.6	20.6
Operating expenses	23.6	20.3	26.1	28.5	32.2	33.5
Total commission and opex	31.2	34.3	41.6	44.3	51.8	54.2
Benefits Paid (Net)	150.0	172.8	142.6	193.8	143.5	149.7
Chg in reserves	175.0	154.5	210.0	(50.6)	226.8	269.5
Total expenses (B)	360.4	367.3	400.5	196.2	428.7	480.4
(A) - (B)	11.5	14.8	13.4	23.2	13.9	15.9
Prov for Tax	0.8	1.2	1.1	1.3	1.1	1.3
Surplus / Deficit	10.7	13.6	12.3	21.9	12.9	14.6
Shareholder's a/c (INR b)	FY17	FY18	FY19	FY20	FY21E	FY22E
Transfer from technical a/c	11.3	10.9	10.8	19.9	11.2	11.9
Income From Investments	6.7	7.4	6.4	6.6	6.4	7.0
Total Income	18.3	18.4	17.3	26.5	17.5	18.9
Other expenses	0.4	0.4	0.4	0.4	0.4	0.4
Contribution to technical a/c	0.0	0.8	5.3	15.0	5.2	5.6
Total Expenses	0.4	1.2	5.6	15.8	5.6	6.0
PBT	17.8	17.2	11.6	10.7	11.9	12.9
PAT	16.8	16.2	11.4	10.7	11.5	12.4
Growth	2%	-4%	-30%	-6%	8%	8%
Premium (INR b) & growth (%)	FY17	FY18	FY19	FY20	FY21E	FY22E
NBP - unweighted	78.6	92.1	103.6	124.9	131.1	144
NBP - wrp	65.0	75.4	73.2	71.1	65.3	77
Renewal premium	144.9	178.6	205.7	209.4	211.4	215
Total premium - unweighted	223.5	270.7	309.3	334.3	342.5	360
NBP growth - unweighted	16.2%	17.1%	12.5%	20.5%	5.0%	10.0%
NBP growth - wrp	27.2%	16.1%	-3.0%	-2.9%	-8.1%	18.2%
Renewal premium growth	16.9%	23.2%	15.2%	1.8%	0.9%	1.9%
Tot. premium growth - unweighted	16.6%	21.1%	14.3%	8.0%	2.5%	5.0%
Durantium main (0/)	FY17	FY18	FY19	FY20	FY21E	FY22E
Premium mix (%) New business - un-wtd	F11/	F119	F119	F1ZU	FYZIE	FYZZE
- Individual mix	88.7%	91.2%	78.5%	63.1%	70.0%	75.0%
- maividual mix - Group mix	11.3%	8.8%	76.5% 21.5%	36.9%	30.0%	25.0%
New business mix - APE	11.5%	0.0%	21.5%	30.9%	30.0%	25.0%
- Participating	9.5%	10.6%	9.0%	12.5%	12.5%	11.8%
	4.8%	5.0%	9.0%	18.3%	22.5%	24.5%
Non-participatingULIPs	4.8 <i>%</i> 85.7%	84.4%	82.0%	69.2%	65.0%	63.7%
Total premium mix - un-wtd	83.7 /6	04.470	82.076	09.276	03.0%	03.776
- Participating	11.7%	12.0%	11.4%	12.2%	10.7%	10.6%
	13.6%	12.8%	15.2%	17.6%	28.6%	29.3%
Non-participatingULIPs	74.8%	75.2%	73.4%	70.2%	60.7%	60.1%
- OLIFS	74.0%	73.2%	73.4%	70.2%	00.7%	00.1%
Indi. Premium sourcing mix (%)	FY17	FY18	FY19	FY20	FY21E	FY22E
Individual agents	23.5%	25.6%	21.8%	21.9%	22.9%	23.9%
Corporate agents-Banks	57.1%	52.6%	55.2%	49.7%	49.5%	49.3%
Direct business	12.8%	16.0%	16.7%	20.1%	22.0%	21.8%
Others	6.6%	5.8%	6.3%	8.3%	5.6%	5.0%

MOTILAL OSWAL ICICI Prudential Life Insurance

Financials and Valuations

Balance sheet (INR b)	FY17	FY18	FY19	FY20	FY21E	FY22E
Sources of Fund	1117	L110	F113	F120	FIZIL	FIZZL
Share Capital	14.4	14.4	14.4	14.4	14.4	14
Shareholders' Fund	64.1	68.8	70.4	72.2	80.3	89
Policy Liabilities	251.7	309.9	385.5	473.6	613.6	788
Prov. for Linked Liab.	839.4	923.1	1,037.0	880.4	1,058.2	1,153
Funds For Future App.	6.0	8.8	10.3	12.3	14.2	1,133
Current liabilities & prov.	28.4	34.5	36.6	33.3	40.0	48
Total	1,247.4	1,418.2	1,630.9	1,560.4	1,804.3	2,092
Application of Funds	_,	2,12012	2,000.5	2,55511	2,00	2,032
Shareholders' inv	66.3	77.5	79.9	74.2	79.4	85.0
Policyholders' inv	270.7	332.9	400.7	467.5	615.1	798
Assets to cover linked liab.	878.8	975.0	1,109.5	970.8	1,058.2	1,153
Loans	0.8	1.5	2.7	4.6	5.2	6
Total	1,247.4	1,418.2	1,630.9	1,560.4	1,804.3	2,092
-	•	•	,	,	•	,
Operating ratios (%)	FY17	FY18	FY19	FY20	FY21E	FY22E
Investment yield (%)	13.0%	8.6%	6.8%	-8.7%	5.5%	6.5%
Commissions / GWP	3.4%	5.2%	5.0%	4.7%	5.7%	5.7%
- first year premiums	7.3%	13.9%	16.0%	16.5%	25.9%	22.9%
- renewal premiums	2.0%	1.9%	1.9%	1.8%	1.8%	1.8%
- single premiums	0.6%	1.9%	1.4%	1.1%	1.1%	1.1%
Operating expenses / GWP	10.5%	7.5%	8.4%	8.5%	9.4%	9.3%
Total expense ratio	13.9%	12.7%	13.4%	13.3%	15.1%	15.1%
Claims / NWP	67.7%	64.5%	46.6%	58.9%	42.4%	42.2%
Solvency margin	289%	252%	215%	194%	189%	170%
Persistency ratios (%)	FY17	FY18	FY19	FY20	FY21E	FY22E
13th Month	85.7%	86.8%	86.2%	85.3%	84.8%	84.4%
25th Month	73.9%	78.3%	77.4%	77.4%	76.7%	76.2%
37th Month	66.8%	68.8%	71.0%	69.0%	69.0%	68.6%
49th Month	59.3%	64.2%	65.0%	66.4%	65.0%	65.0%
61st Month	56.2%	54.5%	58.1%	57.4%	58.5%	57.4%
Profitability ratios	FY17	FY18	FY19	FY20	FY21E	FY22E
VNB margin (%)	10.1%	16.5%	17.0%	21.7%	23.8%	24.6%
RoE (%)	28.7%	24.4%	16.4%	15.0%	15.1%	14.7%
RoIC (%)	34.8%	33.4%	23.5%	22.0%	23.7%	25.5%
Operating ROEV (%)	16.4%	22.8%	20.2%	15.2%	14.9%	14.9%
RoEV (%)	16.0%	16.1%	15.1%	6.5%	14.5%	14.6%
Valuation mater	FV4.7	E)/40	EV4.0	E1/20	51/04 5	5,4225
Valuation ratios	FY17	FY18	FY19	FY20	FY21E	FY22E
Total AUMs (INRb)	1,229.2	1,395.3	1,604.1	1,529.7	1,665.1	1,833
- Of which equity AUMs (%) Dividend (%)	47%	48%	48%	40%	43%	45%
,	38%	69%	49%	24%	18%	20%
Dividend payout ratio (%) EPS (INR)	40%	74%	74%	38%	26%	28%
,	11.7 6.6	11.3	8.0	7.4	8.0	8.6
VNB (INRb) EV (INRb)	161.7	12.9	13.3	16.0	15.5 262.4	19.0
EV/Per share	112.7	187.8	216.1	230.2	263.4	301.8
VIF as % of EV	58%	130.8	150.6 66%	160.4	183.5 67%	210.3
P/VIF	58% 6.7	63%		66%		71%
P/AUM (%)	52%	5.4 46%	4.5 40%	4.2	3.6 38%	3.0
		46%	40%	42%		35%
P/EV (x)	3.9	3.4	2.9 55.7	2.8	2.4 55.3	2.1
P/EPS (x)	37.8	39.3	55.7	59.5	55.3	51.3

NOTES

Explanation of Investment Rating						
Investment Rating	Expected return (over 12-month)					
BUY	>=15%					
SELL	<-10%					
NEUTRAL	< - 10 % to 15%					
UNDER REVIEW	Rating may undergo a change					
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation					

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.nseindia.com, Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated. from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company. MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

11 21 July 2020

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com. CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs,Insurance Products and IPOs.Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.